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had been referred to Loeys and Dietz since they clearly exhibited a
syndromatic phenotype but did not ﬁt other known aneurysm syn-
dromes. Meanwhile the phenotype has broadened and it has been real-
ized that e.g. a biﬁd uvula is not an essential feature in diagnosing LDS
(Loeys et al., 2005).
In 2011, van de Laar and colleagues described a group of patientsAortic aneurysm describes a pathological enlargement of the main
vessel in the body, the aorta,whichultimately leads to dissection or rup-
ture. Aortic dissection is a life-threatening event associated with a mor-
tality of 1–2% per hour.
Over the past decade, the medical community has slowly accepted
the idea that patients presenting with aortic aneurysms and dissections
are part of a wide spectrum of genetically mediated diseases that pres-
ent in syndromic as well a non-syndromic forms. Marfan syndrome
(MFS) has long been the only seriously considered differential diagnosis
in terms of a heritable disorder of connective tissue in patients with aor-
tic aneurysm. MFS is an autosomal dominant disorder affecting about 1
in 5000 individuals. The phenotypic changes ofMFS are imposed bymu-
tations in the gene encoding for the extracellular matrix protein
ﬁbrillin-1 (Dietz et al., 1991). It has been shown that aneurysm forma-
tion in MFS is driven by excessive transforming growth factor-β (TGF-
β) signaling through the “non-canonical” pathway via extracellular
signal-regulated kinase (pERK) (Habashi et al., 2011; Holm et al.,
2011). TGF-β is a ubiquitous cytokine in most mammalian cells and in-
volved in cellular proliferation and differentiation.
Ten years ago Loeys and Dietz identiﬁed a subset of patients sharing
certain features such as a biﬁd uvula, hypertelorism and marked tortu-
osity of the vessels that had not been typically associated with MFS.
The group identiﬁed mutations in the gene encoding for the TGF-β re-
ceptors 1 and 2 as the causative mutation (Loeys et al., 2006; Loeys
et al., 2005). Identifying Loeys-Dietz syndrome (LDS) as a separate enti-
ty was important as patients with LDS suffered from acute aortic dissec-
tion at aortic diameters that had not been considered a cut-off to
proceed to surgery in MFS patients. Therefore, the diagnosis LDS carries
immediate therapeutic consequences and has made genetic testing an
important step in evaluating patientswith aortic aneurysms for surgery.m.2016.09.006.
. This is an open access article underThe initial patients were mostly children with a strong phenotype that
presenting with aortic aneurysms and early onset osteoarthritis (AOS)
and identiﬁed amutation in the gene encoding for SMAD3, a downstream
regulatory protein of the TGF-β pathway as the causative mutation (van
de Laar et al., 2011). Patients presenting with SMAD3 mutations have
meanwhile been classiﬁed as being part of the LDS spectrum.
While it has been shown that TGF-β signaling in LDS patients is al-
tered and results in an increased tissue signature for downstream mo-
lecular events, the mechanism that leads to aneurysm formation is
lesswell established than inMFS. In their current study in EBioMedicine,
van der Pluijm and colleagues present an important contribution to es-
tablish altered TGF-β signaling as the culprit of aneurysm formation in
LDS using Smad3−/− mice that serves as a model for the recently de-
scribed aneurysm-osteoarthritis syndrome, now referred to as type 3
Loeys-Dietz syndrome (van der Pluijm et al., 2016).
The authors saw a marked dilatation of the aorta in Smad3−/−mice
at 6 weeks of age and report 65%mortality in male Smad3−/−mice at 3
months. The authors chose the Smad3−/− mouse model, as the func-
tional consequences of heterozygous mutations seen in people with
LDS are unclear. Nevertheless, data derived from mouse models for
MFS, clearly show phenotypic and functional differences in animals car-
rying a heterozygous FBN1 mutation compared to hypomorphic (e.g.
Fbn1mgR/mgR) or Fbn1−/−mice. Although similarities are seen between
the Smad3−/−mouse model and AOS/LDS3 this might raise the ques-
tion to what extent a Smad3−/−mouse model will be able to recapitu-
late events seen in people with LDS type 3.
The authors show that pSMAD2 and pERK, markers of canonical and
non-canonical TGF-β signaling are increased in tissue of SMAD3−/−
mice before aneurysms develop. Although this is only observational
data, it is further evidence for increased TGF-β signaling being the cause
rather than the effect of aneurysm formation in LDS. The authors then ex-
amined the transcriptional response of vascular smooth muscle cells
(VSMC) in Smad3−/− mice and saw a signiﬁcantly impaired response
compared to Smad3+/+ mice. Furthermore, the authors observed mark-
edly less accumulation of collagen and extracellular matrix (ECM) pro-
teins than in other mouse models for aortic aneurysms.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
27F.S. Schoenhoff / EBioMedicine 12 (2016) 26–27The authors speculate that this diminished ECM accumulation to-
gether with the altered transcriptional response of the VSMC triggers
an immune response that leads to the structural failure they observed
in aortas from Smad3−/−mice. Unfortunately, so far there is no exper-
imental data that challenges parts of this proposed mechanism.
The authors compare their resultswith data derived fromFibulin-4R/R
animals. While this is certainly interesting from a disease model point of
view, there is very little known about the human phenotype. Since
SMAD3 mutations are discussed in the context of LDS and given the
phenotypic overlap with MFS, it might be interesting to extend the
discussion including the well-characterized mouse models for MFS.
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